#1 Clinical Trials Search in Europe

Ly3298176

Tirzepatide, also known as LY3298176, is an innovative drug being studied in various clinical trials for its potential in treating type 2 diabetes, obesity, and related health conditions. These trials aim to evaluate the efficacy, safety, and long-term effects of tirzepatide in different patient populations, including adults and adolescents. The studies compare tirzepatide to existing treatments or placebos, focusing on outcomes such as blood sugar control, weight loss, and improvements in weight-related health issues.

Table of Contents

What is Tirzepatide?

Tirzepatide, also known by its research code LY3298176, is a new medication being studied for the treatment of obesity and related health conditions[1]. It is developed by Eli Lilly and Company and is currently undergoing clinical trials to evaluate its safety and effectiveness[2].

How Tirzepatide Works

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This means it mimics the action of two naturally occurring hormones in the body that help regulate blood sugar levels and appetite[3]. By targeting both GIP and GLP-1 receptors, tirzepatide may offer enhanced benefits compared to medications that target only one of these pathways.

Conditions Treated by Tirzepatide

Tirzepatide is being investigated for the treatment of several conditions:

  • Obesity: For adults who have a body mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related health condition[1].
  • Overweight: For adults with a BMI between 25 and 29.9 who also have weight-related health issues[1].
  • Weight-related comorbidities: These may include conditions such as high blood pressure, high cholesterol, sleep apnea, or prediabetes[1].
  • Chronic Kidney Disease: In people with overweight or obesity, with or without type 2 diabetes[4].
  • Wolfram syndrome type 1: A rare genetic disorder that affects multiple body systems, including diabetes[5].

Effectiveness of Tirzepatide

Clinical trials are ongoing to evaluate the effectiveness of tirzepatide. Some key findings from current studies include:

  • Tirzepatide has shown superiority to placebo in reducing body weight. In one study, the main goal is to demonstrate that tirzepatide at its maximum tolerated dose (MTD) is superior to placebo for the mean percent decrease in weight loss[1].
  • The medication is being compared to other treatments, such as semaglutide 2.4 mg, to assess its effectiveness in weight loss[1].
  • Researchers are looking at various levels of weight loss, including the percentage of participants who achieve 10%, 15%, 20%, 25%, and even 30% body weight reduction[1].
  • In addition to weight loss, tirzepatide is being studied for its effects on waist circumference and body mass index (BMI)[1].

How Tirzepatide is Administered

Tirzepatide is administered as a subcutaneous injection, which means it is injected just under the skin. The medication is typically given once weekly, with doses being gradually increased over time to reach the maximum tolerated dose[1][5]. The exact dosing may vary depending on the specific condition being treated and individual patient factors.

Ongoing Research on Tirzepatide

Several clinical trials are currently underway to further investigate the potential of tirzepatide:

  • SURMOUNT-5 study: This trial is comparing tirzepatide to semaglutide 2.4 mg in adults with obesity or overweight with weight-related comorbidities[1].
  • SURMOUNT-MMO study: This research is investigating whether tirzepatide can reduce morbidity and mortality in adults with obesity[2].
  • SURMOUNT-ADOLESCENTS and SURMOUNT-ADOLESCENTS-2 studies: These trials are evaluating the safety and efficacy of tirzepatide in adolescents with obesity or overweight with weight-related comorbidities[3][6].
  • TREASURE-CKD study: This research is looking at the effects of tirzepatide on kidney function in people with overweight or obesity and chronic kidney disease, with or without type 2 diabetes[4].
  • Wolfram syndrome type 1 study: A trial is investigating tirzepatide’s potential to increase endogenous insulin production in patients with this rare genetic disorder[5].

Potential Side Effects and Precautions

While tirzepatide is still being studied, there are some potential side effects and precautions to be aware of:

  • People with a history of pancreatitis (inflammation of the pancreas) may not be eligible to take tirzepatide[3][5].
  • Those with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2 should not use tirzepatide[3][5].
  • The medication is not recommended for people with type 1 diabetes[1].
  • Patients with severe kidney impairment may not be eligible for treatment with tirzepatide[1].
  • As with any medication, there may be other side effects or interactions. It’s important to discuss all potential risks and benefits with a healthcare provider.

Tirzepatide represents a promising new approach to treating obesity and related health conditions. As research continues, we’ll learn more about its long-term effectiveness and safety profile. If you’re considering treatment options for obesity or related conditions, it’s essential to consult with a healthcare professional to determine the best approach for your individual needs.

Aspect Details
Drug Name Tirzepatide (LY3298176)
Conditions Studied Type 2 Diabetes, Obesity, Overweight with related health issues, Chronic Kidney Disease
Patient Populations Adults, Adolescents
Administration Method Subcutaneous injection, typically once weekly
Primary Outcomes Change in HbA1c, Weight loss, BMI reduction
Secondary Outcomes Improvement in weight-related comorbidities, Changes in waist circumference, Quality of life measures
Study Designs Randomized, Placebo-controlled, Active-comparator trials
Study Durations Ranging from 40 weeks to 324 weeks (6.2 years)

FAQ

  • What is tirzepatide and how does it work? Tirzepatide (LY3298176) is a new medication being studied for treating type 2 diabetes and obesity. It works by mimicking certain hormones in the body that help control blood sugar and appetite.
  • What conditions is tirzepatide being studied for? Tirzepatide is being studied for type 2 diabetes, obesity, overweight with related health issues, and chronic kidney disease. It's being tested in both adults and adolescents.
  • How is tirzepatide given to patients in clinical trials? In the clinical trials, tirzepatide is given as a solution for injection, usually administered once a week under the skin (subcutaneously).
  • What are some of the main goals of the tirzepatide clinical trials? The main goals include evaluating its effectiveness in lowering blood sugar levels (HbA1c), reducing body weight, improving weight-related health issues, and assessing its safety in different patient groups.
  • Are there any specific patient groups being studied? Yes, the trials are studying tirzepatide in various groups, including adults with type 2 diabetes, adults with obesity or overweight, adolescents with obesity, and people with chronic kidney disease.

Ongoing Clinical Trials on Ly3298176

  • Study Comparing Tirzepatide and Semaglutide for Weight Loss in Adults with Obesity or Overweight and Related Health Issues

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Poland

Glossary

  • Tirzepatide: An investigational drug (also known as LY3298176) being studied for the treatment of type 2 diabetes, obesity, and related conditions.
  • HbA1c: Hemoglobin A1c, a blood test that measures average blood sugar levels over the past 2-3 months.
  • BMI: Body Mass Index, a measure used to determine if a person is at a healthy weight for their height.
  • Type 2 Diabetes: A chronic condition that affects the way your body processes blood sugar (glucose).
  • Obesity: A complex disease involving an excessive amount of body fat, typically defined as a BMI of 30 or higher.
  • Chronic Kidney Disease: A condition characterized by gradual loss of kidney function over time.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Subcutaneous: Beneath the skin. In these trials, it refers to injections given just under the skin.
  • Efficacy: The ability of a drug to produce the desired effect.
  • Comorbidity: The presence of one or more additional conditions often co-occurring with a primary condition.

References

  1. http://clinicaltrials.eu/trial/study-comparing-tirzepatide-and-semaglutide-for-weight-loss-in-adults-with-obesity-or-overweight-and-related-health-issues/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-tirzepatide-in-reducing-health-risks-and-death-in-adults-with-obesity/
  3. http://clinicaltrials.eu/trial/study-of-tirzepatide-for-adolescents-with-obesity-or-overweight-and-related-health-issues/
  4. http://clinicaltrials.eu/trial/study-of-tirzepatide-and-placebo-for-people-with-overweight-or-obesity-and-chronic-kidney-disease-with-or-without-type-2-diabetes/
  5. http://clinicaltrials.eu/trial/study-on-tirzepatide-for-improving-insulin-production-in-patients-with-wolfram-syndrome-type-1/
  6. http://clinicaltrials.eu/trial/study-of-tirzepatide-for-reducing-obesity-and-related-health-issues-in-adolescents/